{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:46:37Z","timestamp":1791492397641,"version":"4.3.4"},"reference-count":91,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Ministry of Science and Innovation Spain","award":["AGL2015-65673-R"],"award-info":[{"award-number":["AGL2015-65673-R"]}]},{"name":"ERA-NET European Union","award":["BLAAT ID: 67"],"award-info":[{"award-number":["BLAAT ID: 67"]}]},{"name":"Program of Science, Technology and Innovation Principado de Asturias","award":["GRUPIN14-139"],"award-info":[{"award-number":["GRUPIN14-139"]}]},{"name":"FEDER EU funds","award":["GRUPIN14-139"],"award-info":[{"award-number":["GRUPIN14-139"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2018,3,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) is one of the most threatening microorganisms for global human health. The current strategies to reduce the impact of\n                    <jats:italic>S.\u00a0aureus<\/jats:italic>\n                    include a restrictive control of worldwide antibiotic use, prophylactic measures to hinder contamination, and the search for novel antimicrobials to treat human and animal infections caused by this bacterium. The last strategy is currently the focus of considerable research. In this regard, phage lytic proteins (endolysins and virion-associated peptidoglycan hydrolases [VAPGHs]) have been proposed as suitable candidates. Indeed, these proteins display narrow-spectrum antimicrobial activity and a virtual lack of bacterial-resistance development. Additionally, the therapeutic use of phage lytic proteins in\n                    <jats:italic>S.\u00a0aureus<\/jats:italic>\n                    animal infection models is yielding promising results, showing good efficacy without apparent side effects. Nonetheless, human clinical trials are still in progress, and data are not available yet. This minireview also analyzes the main obstacles for introducing phage lytic proteins as human therapeutics against\n                    <jats:italic>S.\u00a0aureus<\/jats:italic>\n                    infections. Besides the common technological problems derived from large-scale production of therapeutic proteins, a major setback is the lack of a proper legal framework regulating their use. In that sense, the relevant health authorities should urgently have a timely discussion about these new antimicrobials. On the other hand, the research community should provide data to dispel any doubts regarding their efficacy and safety. Overall, the appropriate scientific data and regulatory framework will encourage pharmaceutical companies to invest in these promising antimicrobials.\n                  <\/jats:p>","DOI":"10.1128\/mbio.01923-17","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T08:23:48Z","timestamp":1516609428000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":122,"title":["Are Phage Lytic Proteins the Secret Weapon To Kill\n                    <i>Staphylococcus aureus<\/i>\n                    ?"],"prefix":"10.1128","volume":"9","author":[{"given":"Diana","family":"Guti\u00e9rrez","sequence":"first","affiliation":[{"name":"Instituto de Productos L\u00e1cteos de Asturias (IPLA-CSIC), Villaviciosa, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Instituto de Productos L\u00e1cteos de Asturias (IPLA-CSIC), Villaviciosa, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1577-9905","authenticated-orcid":false,"given":"Ana","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Instituto de Productos L\u00e1cteos de Asturias (IPLA-CSIC), Villaviciosa, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Instituto de Productos L\u00e1cteos de Asturias (IPLA-CSIC), Villaviciosa, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antimicrobial resistance, global report on surveillance 2014","author":"WHO","year":"2014","unstructured":"WHO. 2014. Antimicrobial resistance, global report on surveillance 2014. WHO, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","first-page":"63","article-title":"Staphylococcus aureus and food poisoning","volume":"2","author":"Le Loir Y","year":"2003","unstructured":"Le Loir Y, Baron F, Gautier M. 2003. Staphylococcus aureus and food poisoning. Genet Mol Res 2:63\u201376.","journal-title":"Genet Mol Res"},{"key":"e_1_3_2_4_2","first-page":"4329","article-title":"The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2014","volume":"13","author":"EFSA, ECDC","year":"2016","unstructured":"EFSA, ECDC. 2016. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2014. EFSA J 13:4329.","journal-title":"EFSA J"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fm.2015.04.007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.10.001"},{"key":"e_1_3_2_7_2","unstructured":"WHO. 2012. The evolving threat of antimicrobial resistance: options for action. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-9-48"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/1574-6976.12006"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890108995959"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2008.09.012"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.723675"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.3.4.463"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03277-12"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2007.00099.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2009.04.023"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.188.7.2463-2472.2006"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01625-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-016-7747-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03065-05"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004109"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-133"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01831-08"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2009.01541.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2017.02.011"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00217-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/1574-6968.12104"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep25063"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.13634"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/08927014.2014.905927"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-009-2386-9"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01616-06"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.011"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/625341"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-014-5930-1"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep40182"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107307"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-015-6460-1"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01632"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep01584"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6831-6-S1-S16"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00890-10"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064671"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02724-16"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp159"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-11-226"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.4161\/bbug.1.6.13422"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/521305"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01144-10"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2016.08.003"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku552"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-011-9939-8"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.07050-11"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2016.06.001"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00126-14"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit637"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165646"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-280"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02232-13"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12613"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000473872"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02629-16"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijfoodmicro.2016.12.007"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijfoodmicro.2010.04.029"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054828"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijfoodmicro.2008.08.010"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tifs.2010.04.010"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-015-7185-x"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2015.09.058"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00172"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.4161\/bbug.1.2.10484"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/pbi.12703"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2016.1222994"},{"key":"e_1_3_2_74_2","volume-title":"Proteins: biochemistry and biotechnology","author":"Walsh G","year":"2014","unstructured":"Walsh G. 2014. Proteins: biochemistry and biotechnology, 2nd ed. John Wiley & Sons, Chichester, England.","edition":"2"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2013.04.013"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-016-2115-7"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3776"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.11.030"},{"key":"e_1_3_2_79_2","volume-title":"Guidelines relating to the application of the Council Directive 90\/385\/EEC on active implantable medical devices","author":"European Commission","year":"2001","unstructured":"European Commission. 2001. Medical devices: guidance document. Guidelines relating to the application of the Council Directive 90\/385\/EEC on active implantable medical devices. European Commission, Brussels, Belgium. http:\/\/ec.europa.eu\/consumers\/sectors\/medical-devices\/files\/meddev\/2_1_3____07-2001_en.pdf. Accessed April 2017."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01209"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0175-0"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.09.003"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.02.005"},{"key":"e_1_3_2_84_2","first-page":"18","volume-title":"Cost to develop and win marketing approval for a new drug is $2.6 billion","author":"Tufts Center for the Study of Drug Development","year":"2014","unstructured":"Tufts Center for the Study of Drug Development. 18 November 2014. Cost to develop and win marketing approval for a new drug is $2.6 billion. News of the Tufts Center for the Study of Drug Development, Boston, MA. http:\/\/csdd.tufts.edu\/news\/complete_story\/pr_tufts_csdd_2014_cost_study. Accessed April 2017."},{"key":"e_1_3_2_85_2","unstructured":"The European Parliament and the Council of the European Union. 2001. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Off J Eur Union L 311\/67\u2013L 311\/128. https:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-1\/dir_2001_83_cons2009\/2001_83_cons2009_en.pdf."},{"key":"e_1_3_2_86_2","unstructured":"The European Parliament and the Council of the European Union. 2004. Regulation (EC) no 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union L 136\/1\u2013L 136\/33. http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF."},{"key":"e_1_3_2_87_2","unstructured":"The European Parliament and the Council of the European Union. 2008. Regulation (EC) no 1333\/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. Off J Eur Union L 354 31.12.2008. https:\/\/www.fsai.ie\/uploadedFiles\/Consol_Reg1333_2008.pdf."},{"key":"e_1_3_2_88_2","volume-title":"BPR legislation","author":"European Chemicals Agency","year":"2008","unstructured":"European Chemicals Agency. 2008. BPR legislation. ECHA, Helsinki, Finland. https:\/\/echa.europa.eu\/regulations\/biocidal-products-regulation\/legislation."},{"key":"e_1_3_2_89_2","volume-title":"Federal Insecticide, Fungicide, and Rodenticide Act. 36 Stat 331","author":"US Congress.","year":"1910","unstructured":"US Congress. 1910. Federal Insecticide, Fungicide, and Rodenticide Act. 36 Stat 331. US Congress, Washington, DC."},{"key":"e_1_3_2_90_2","volume-title":"Public law 94-295","author":"US Congress","year":"1966","unstructured":"US Congress. 1966. Medical device amendments of 1966. Public law 94-295. US Congress, Washington, DC. https:\/\/www.gpo.gov\/fdsys\/pkg\/STATUTE-90\/pdf\/STATUTE-90-Pg539.pdf."},{"key":"e_1_3_2_91_2","volume-title":"Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 USC, chapter 9","author":"U.S. Congress","year":"1938","unstructured":"U.S. Congress. 1938. Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 USC, chapter 9. US Congress, Washington, DC. https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/FederalFoodDrugandCosmeticActFDCAct\/default.htm."},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.07621-11"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.01923-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.01923-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T21:35:50Z","timestamp":1646688950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mBio.01923-17"}},"subtitle":[],"editor":[{"given":"Michael S.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3,7]]}},"alternative-id":["10.1128\/mBio.01923-17"],"URL":"https:\/\/doi.org\/10.1128\/mbio.01923-17","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732563716.793543668","asserted-by":"object"}]},"ISSN":["2161-2129","2150-7511"],"issn-type":[{"value":"2161-2129","type":"print"},{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"2018-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01923-17"}}